Press "Enter" to skip to content

Merck KGaA says currency headwinds quell drug gains in Q4

Quarterly earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, slipped to 950 million euros ($1.07 billion).

Original source:

Also Read:   Mumbai: Doctors to take relook at Rs 40,000 per vial Tocilizumab’s use in severe cases